Table 6

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer according to stage among screened women, National Institutes of Health–AARP Study

In situ breast cancer
 Invasive breast cancer

NSAID use
 Number of cancers
 Person-years
 Relative riska
 95% confidence interval
 P value for trend
 Number of cancers
 Person-years
 Relative riska
 95% confidence interval
 P value for trend
Aspirin useb









     Never
 241
 192,125
 1.00 (referent)
0.02
 916
 194,396
 1.00 (referent)
0.15
     <1/week
 180
 179,747
 0.77
 0.63 to 0.93
847
 181,986
 0.98
 0.89 to 1.07
     1–6/week
 97
 90,680
 0.82
 0.65 to 1.05
402
 91,715
 0.90
 0.80 to 1.01
     1+/day
 96
 99,793
 0.75
 0.59 to 0.95
476
 101,064
 0.95
 0.85 to 1.06
Non-aspirin NSAID useb









     Never
 218
 209,044
 1.00 (referent)
0.50
 982
 211,655
 1.00 (referent)
0.62
     <1/week
 222
 185,624
 1.16
 0.95 to 1.40
852
 187,741
 0.98
 0.89 to 1.07
     1–6/week
 97
 90,035
 1.03
 0.81 to 1.31
428
 91,161
 1.03
 0.92 to 1.16
     1+/day
 76
 77,462
 0.89
 0.69 to 1.16
384
 78,439
 1.02
 0.91 to 1.15

This analysis was restricted to women who reported ≥2 mammograms in the past 3 years. aAdjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative. bThese models also include terms for frequency of use of opposite NSAID type.

Gierach et al. Breast Cancer Research 2008 10:R38   doi:10.1186/bcr2089